Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Hematology"
DOI: 10.1007/s12185-019-02616-y
Abstract: Aberrant expression of the interleukin-3 receptor alpha chain (IL3RA or CD123) is frequently observed in patients with a subset of leukemic disorders, including acute myeloid leukemia (AML), particularly in leukemia stem cells. We analyzed the… read more here.
Keywords: clinical outcomes; myeloid leukemia; novo aml; expression ... See more keywords
Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML.
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia research"
DOI: 10.1016/j.leukres.2018.05.013
Abstract: CHEK2 plays a key role in cellular response to DNA damage, and also in regulation of mitosis and maintenance of chromosomal stability. In patients newly diagnosed with myelodysplastic syndrome (MDS, n = 107) or acute myeloid leukemia… read more here.
Keywords: mutations chek2; risk; constitutional mutations; chek2 ... See more keywords
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-01-828467
Abstract: Acute myeloid leukemia (AML) with mutated NPM1 is a newly recognized separate entity in the revised 2016 World Health Organization classification and is associated with a favorable prognosis. Although previous studies have evaluated NPM1 in… read more here.
Keywords: high npm1; novo aml; mutant allele; allele burden ... See more keywords
Inferior Outcome of Allogeneic Stem Cell Transplantation in First Complete Remission for Secondary AML As Compared to De Novo Disease: Results from a Retrospective, Registry-Based Analysis on Behalf of the Acute Leukemia Working Party of the EBMT
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113779
Abstract: Background: Acute myeloid leukemia (AML) secondary to haematological neoplasia or other malignant diseases, defined as secondary AML (sAML), is thought to have an inferior prognosis as compared with de novo AML. However, when corrected for… read more here.
Keywords: cell; analysis; saml; novo aml ... See more keywords
The Expression of BTG1 in De Novo AML Patients Regulated By Demethylation of Decitabine and Its Evaluation in the Deep Remission of Patients
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-205864
Abstract: Background As an important hypomethylating agent, decitabine has shown promising efficacy in treating acute myeloid leukemia (AML), including de novo AML patients. However, as AML is a heterogeneous disease, not all de novo patients can… read more here.
Keywords: novo aml; aml patients; expression; decitabine ... See more keywords
Therapy-related AML (t-AML) on the rise: A national perspective on evolving trends, treatment outcomes, and prognostic implications in hospitalized patients
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5181
Abstract: Introduction: Therapy-related Acute Myeloid Leukemia (t-AML) is defined as a type of Acute Myeloid Leukemia (AML) that arises from the mutational consequences of prior cytotoxic, radiation, immunosuppressive, or combination therapies for unrelated diseases. Approximately 5-15%… read more here.
Keywords: novo aml; hospital; hospitalized patients; therapy ... See more keywords
Morphologic and Molecular Characteristics of De Novo AML With JAK2 V617F Mutation.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2017.0106
Abstract: Background:JAK2 V617F mutation (mut) in acute myeloid leukemia (AML) is rare. We describe the clinicopathologic findings of a single-institution series of 11 de novo AML cases with JAK2 V617. Methods: We identified cases of de… read more here.
Keywords: jak2 v617f; v617f mutation; novo aml; aml ... See more keywords